Entrada Therapeutics (TRDA) Q1 2026 Earnings
Entrada Therapeutics reported Q1 2026 revenue of $875.0K (-95.7% YoY), missed analyst consensus of $2.9M by $2.0M. Diluted EPS came in at $-0.95 (-126.2% YoY), beat the $-1.06 consensus by $0.11.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Entrada Therapeutics's Q1 2026 earnings report.
Entrada Therapeutics (TRDA) reported Q1 2026 earnings on May 7, 2026 before market open.
Entrada Therapeutics reported revenue of $875.0K and diluted EPS of $-0.95 for Q1 2026.
Revenue missed the consensus estimate of $2.9M by $2.0M. EPS beat the consensus estimate of $-1.06 by $0.11.
Compared to the same quarter a year prior, revenue declined 95.7% from $20.6M a year earlier and diluted EPS declined 126.2% from $-0.42.
You can read the 8-K earnings release (0001689375-26-000027) and the 10-Q periodic report (0001689375-26-000028) directly on SEC EDGAR. The filing index links above go to sec.gov.